Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LASIK correction of myopic refractive errors · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| wavefront-guided LASIK | EXPERIMENTAL | LASIK correction of myopic refractive errors. Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System. |
| Name | Type | Description |
|---|---|---|
| LASIK correction of myopic refractive errors | DEVICE | Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System |
Inclusion Criteria: * 18 years of age or greater * Best Spectacle Corrected Visual Acuity (BSCVA) of 20/20 or better * Uncorrected visual acuity (UCVA) of 20/40 or worse * Less than 0.75D difference between cycloplegic and manifest refraction sphere. * Demonstration of refractive stability * Antici...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Cooper Companies, Inc. | COO | 3 | N/A | Undisclosed |
| Bausch + Lomb Corporation | BLCO | 4 | N/A | Undisclosed |
| Johnson & Johnson | JNJ | 1 | N/A | Undisclosed |
| Alcon AG | ALC | 2 | N/A | Undisclosed |
| S-Alpha Therapeutics, Inc. | YCBD | 1 | N/A | Undisclosed |
LASIK correction of myopic refractive errors is a surgical procedure used to treat myopia, or nearsightedness. It aims to reshape the cornea to correct refractive errors and reduce dependence on glasses or contact lenses. The procedure is being studied in a Phase 3 clinical trial for patients with myopia.
LASIK correction of myopic refractive errors is developed by Abbott Laboratories, a company traded on the New York Stock Exchange under the ticker ABT. Abbott Laboratories is conducting clinical research on this procedure for the treatment of myopia.
LASIK correction of myopic refractive errors is in Phase 3 clinical development. It is an investigational procedure and has not been approved by the FDA. The Phase 3 trial has been completed, with 170 participants enrolled.
LASIK correction of myopic refractive errors has one completed Phase 3 clinical trial, identified as NCT01663363. The trial, titled 'Safety and Effectiveness of Wavefront-Guided LASIK Corrections of Myopic Refractive Errors,' enrolled 170 participants with myopia and was an uncontrolled, non-randomized study.
LASIK correction of myopic refractive errors is being studied as a wavefront-guided LASIK procedure. The clinical trial NCT01663363 specifically evaluates wavefront-guided LASIK corrections for myopic refractive errors, indicating that the procedure uses wavefront technology to guide the laser treatment.